Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study
Adugnaw Zeleke Alem, Ejigu Gebeye Zeleke, Temesgen Yihunie Akalu Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Science, University of Gondar, Gondar, EthiopiaCorrespondence: Adugnaw Zeleke Alem Email aduzeleke2201@gmail.comBackground: Early...
Guardado en:
Autores principales: | Zeleke Alem A, Gebeye Zeleke E, Akalu TY |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/19f08aa655dc400e86dfdbf03757415f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival
por: Bin Huang, et al.
Publicado: (2021) -
Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients
por: Yin Jin, et al.
Publicado: (2021) -
Adjuvant systemic therapy in older women with breast cancer
por: Leone J, et al.
Publicado: (2016) -
The Results and Outcomes of Rectal Cancer Treatment in the Era of Adjuvant Chemoradiation
por: Ahmad Izadpanah, et al.
Publicado: (2019) -
Inmunohistoquímica convencional como predictor de respuesta y sobrevida en pacientes con cáncer de mama tratadas con quimioterapia preoperatoria: Experiencia de un centro
por: Acevedo,Francisco, et al.
Publicado: (2015)